MODIFICATION
65 -- 65-Single analysis kit for Genomics Profiling
- Notice Date
- 9/12/2002
- Notice Type
- Modification
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20162-NQ
- Response Due
- 9/18/2002
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov
- Small Business Set-Aside
- Total Small Business
- Description
- The National Institutes of Health (NIH), National Cancer Institute (NCI), Center of Cancer Research, Neuro Oncology Branch (NOB), intends to procure on a sole-source basis with Spectral Genomics, Inc., 8080 NorthStadium Drive, Houston, TX 77054 100 Special Analysis - Single Kit Genomic Profiling (2-4Mb) Kits used to conduct large-scale gene expression analysis of thousands of human glioma tissues using microarray. Genomic profiling is the technique of looking at copy changes across the entire chromosome and performing a linear plot across the chromosome in a Megabase resolution. This is very similar to "expression profiling" whereby one would line up genes from any particular region of the genome and look at the change of the number of copies at each position of each gene. In the case of genomic analysis it is referred to as "genomic profiling". Spectral Genomics arrays make use of Bacterial Artificial Chromosome (BAC) which can be used in the cloning of large DNA fragments, on average approximately 200kb long, and has been used as one of the cloning vectors of choice in the sequencing of the human and mouse genomes. Spectral Genomic employs a unique patented approach (Patent #6,048,596) to produce a series of BAC arrays that are ideal for array-based genome profiling. These arrays allow the researcher the capacity to perform the sort of high-resolution genome scans required for the detection of chromosomal imbalances that are common events in most tumors and many congenital abnormalities. Using Spectral Genomics, BAC arrays will permit the analysis of genomic profiling (CGH) of genes discovered by our microarray studies. The reagent is essential for the NOB lab to better understand the molecular mechanisms of glioma, discovery of better diagnosis methods and prediction of clinical therapeutic outcomes, e.g., patient survival rate. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI researcher to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington, D.C. time) on September 18, 2002. If you have any questions, please contact Cynthia Brown, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. The NAICS Code:541380 and the business size standard is $6.0 million. No collect calls for faxed copies of capability statements will be accepted.
- Record
- SN00164373-W 20020914/020912213211 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |